We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study
Read MoreHide Full Article
Bristol-Myers Squibb Company (BMY - Free Report) suffered a setback as a late-stage study evaluating its blockbuster immuno-oncology drug Opdivo for the treatment of malignant brain tumor failed to meet its primary endpoint.
The phase III randomized, multi-center study CheckMate -548 is evaluating the addition of Opdivo to the current standard of care (Temodal and radiation therapy) compared to the standard of care alone in patients with newly diagnosed glioblastoma multiforme (GBM) that is O6-methylguanine-DNA methyltransferase (MGMT)-methylated.
However, the study did not meet the primary endpoint of progression-free survival (PFS) per blinded independent central review (BICR).
Nevertheless, the data monitoring committee recommended that the study continue as planned to allow the other primary endpoint, overall survival (OS), is yet to mature. The company remains blinded to all study data. The secondary endpoints are investigator assessed PFS, and OS rate up to two years.
Earlier, the phase III CheckMate-498 trial evaluating Opdivo plus radiation compared to temozolomide plus radiation in patients with newly diagnosed O6- MGMT-unmethylated GBM missed its primary goal of overall survival at final analysis.
Bristol-Myers’ shares have decreased 6.7% in the year so far, wider than the industry’s decline of 0.6%.
Meanwhile, Karyopharm Therapeutics (KPTI - Free Report) is also evaluating Xpovio for the treatment of glioblastoma.
Opdivo is Bristol-Myers’ primary driver. It is currently approved in the United States, the EU, Japan and across other countries for several cancer indications. The company is working on expanding the label of Opdivo further.
However, the drug faces stiff competition and has endured debacles of late. It confronts rivalry from Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda. Additionally, a close contest is on the rise in this category with the presence of Roche’s (RHHBY - Free Report) Tecentriq. Both Keytruda and Tecentriq are approved for the first-line non-small cell lung cancer (NSCLC), which has the largest patient population among all cancer indications.
We remind investors that the part 1a of the phase III Checkmate-227 study evaluating Opdivo combined with low-dose Yervoy compared to chemotherapy only, succeeds in meeting the co-primary endpoint of overall survival in first-line NSCLC patients whose tumors express PD-L1 ≥1%. However, part 2 of the study evaluating Opdivo plus chemotherapy compared to chemotherapy alone was unable to meet its primary endpoint of overall survival in first-line non-squamous NSCLC patients, regardless of PD-L1 status.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study
Bristol-Myers Squibb Company (BMY - Free Report) suffered a setback as a late-stage study evaluating its blockbuster immuno-oncology drug Opdivo for the treatment of malignant brain tumor failed to meet its primary endpoint.
The phase III randomized, multi-center study CheckMate -548 is evaluating the addition of Opdivo to the current standard of care (Temodal and radiation therapy) compared to the standard of care alone in patients with newly diagnosed glioblastoma multiforme (GBM) that is O6-methylguanine-DNA methyltransferase (MGMT)-methylated.
However, the study did not meet the primary endpoint of progression-free survival (PFS) per blinded independent central review (BICR).
Nevertheless, the data monitoring committee recommended that the study continue as planned to allow the other primary endpoint, overall survival (OS), is yet to mature. The company remains blinded to all study data. The secondary endpoints are investigator assessed PFS, and OS rate up to two years.
Earlier, the phase III CheckMate-498 trial evaluating Opdivo plus radiation compared to temozolomide plus radiation in patients with newly diagnosed O6- MGMT-unmethylated GBM missed its primary goal of overall survival at final analysis.
Bristol-Myers’ shares have decreased 6.7% in the year so far, wider than the industry’s decline of 0.6%.
Meanwhile, Karyopharm Therapeutics (KPTI - Free Report) is also evaluating Xpovio for the treatment of glioblastoma.
Opdivo is Bristol-Myers’ primary driver. It is currently approved in the United States, the EU, Japan and across other countries for several cancer indications. The company is working on expanding the label of Opdivo further.
However, the drug faces stiff competition and has endured debacles of late. It confronts rivalry from Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda. Additionally, a close contest is on the rise in this category with the presence of Roche’s (RHHBY - Free Report) Tecentriq. Both Keytruda and Tecentriq are approved for the first-line non-small cell lung cancer (NSCLC), which has the largest patient population among all cancer indications.
We remind investors that the part 1a of the phase III Checkmate-227 study evaluating Opdivo combined with low-dose Yervoy compared to chemotherapy only, succeeds in meeting the co-primary endpoint of overall survival in first-line NSCLC patients whose tumors express PD-L1 ≥1%. However, part 2 of the study evaluating Opdivo plus chemotherapy compared to chemotherapy alone was unable to meet its primary endpoint of overall survival in first-line non-squamous NSCLC patients, regardless of PD-L1 status.
Bristol-Myers currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>